RNC Capital Management LLC Has $39.03 Million Position in Kenvue Inc. $KVUE

RNC Capital Management LLC reduced its position in shares of Kenvue Inc. (NYSE:KVUEFree Report) by 1.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,864,647 shares of the company’s stock after selling 20,538 shares during the period. Kenvue makes up about 1.9% of RNC Capital Management LLC’s portfolio, making the stock its 28th biggest holding. RNC Capital Management LLC owned approximately 0.10% of Kenvue worth $39,027,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in KVUE. GAMMA Investing LLC lifted its holdings in Kenvue by 33.2% during the 1st quarter. GAMMA Investing LLC now owns 24,778 shares of the company’s stock worth $594,000 after purchasing an additional 6,169 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in Kenvue by 4.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock worth $2,545,000 after acquiring an additional 4,034 shares during the period. Continuum Advisory LLC increased its stake in Kenvue by 2,071.1% during the 1st quarter. Continuum Advisory LLC now owns 1,954 shares of the company’s stock worth $47,000 after acquiring an additional 1,864 shares during the period. Oppenheimer & Co. Inc. increased its stake in shares of Kenvue by 5.3% in the 1st quarter. Oppenheimer & Co. Inc. now owns 172,255 shares of the company’s stock valued at $4,131,000 after purchasing an additional 8,693 shares during the last quarter. Finally, Asset Management One Co. Ltd. increased its stake in shares of Kenvue by 6.9% in the 1st quarter. Asset Management One Co. Ltd. now owns 801,376 shares of the company’s stock valued at $19,217,000 after purchasing an additional 51,796 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Royal Bank Of Canada decreased their price target on Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research note on Friday, August 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research note on Tuesday, October 14th. Redburn Partners set a $22.00 price target on Kenvue in a research note on Friday, September 26th. Evercore ISI decreased their price target on Kenvue from $23.00 to $18.00 and set an “in-line” rating on the stock in a research note on Tuesday, September 23rd. Finally, Zacks Research upgraded Kenvue to a “strong sell” rating in a research report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Kenvue presently has an average rating of “Hold” and a consensus price target of $21.18.

View Our Latest Stock Report on KVUE

Kenvue Trading Up 1.8%

NYSE KVUE opened at $15.20 on Thursday. The business’s 50-day moving average price is $18.15 and its two-hundred day moving average price is $20.89. Kenvue Inc. has a 12 month low of $14.05 and a 12 month high of $25.17. The firm has a market capitalization of $29.16 billion, a PE ratio of 20.53, a price-to-earnings-growth ratio of 2.15 and a beta of 0.72. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUEGet Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. During the same quarter in the previous year, the company posted $0.32 EPS. The business’s revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were paid a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.5%. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio (DPR) is presently 112.16%.

Kenvue Profile

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Featured Articles

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUEFree Report).

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.